The ROE as of September 2024 (TTM) for Phathom Pharmaceuticals, Inc. (PHAT) is 251.33%

According to Phathom Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is 251.33%. This represents a change of 124.62% compared to the average of 111.89% of the last 4 quarters.

Phathom Pharmaceuticals, Inc. (PHAT) Historical ROE (quarterly & annually)

How has PHAT ROE performed in the past?

The mean historical ROE of Phathom Pharmaceuticals, Inc. over the last ten years is 51.57%. The current 251.33% ROE has changed 387.34% with respect to the historical average. Over the past ten years (40 quarters), PHAT's ROE was at its highest in in the June 2022 quarter at 727.43%. The ROE was at its lowest in in the June 2023 quarter at -232.76%.

Phathom Pharmaceuticals, Inc. (PHAT) ROE by Quarter and Year

Discovering the peaks and valleys of Phathom Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Phathom Pharmaceuticals, Inc. (PHAT) Average ROE

How has PHAT ROE performed in the past?

The current ROE of Phathom Pharmaceuticals, Inc. (PHAT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Phathom Pharmaceuticals, Inc. (PHAT) ROE vs. Peers

How is PHAT’s ROE compared to its peers?

Phathom Pharmaceuticals, Inc.’s ROE is greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than Blueprint Medicines Corporation (-85.25%), greater than Lyra Therapeutics, Inc. (-143.74%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Inozyme Pharma, Inc. (-68.93%), greater than VectivBio Holding AG (-56.92%), greater than Kiniksa Pharmaceuticals, Ltd. (-5.10%), greater than Structure Therapeutics Inc. (-20.15%), greater than Karuna Therapeutics, Inc. (-30.79%), greater than Immix Biopharma, Inc. (-86.48%), less than CNS Pharmaceuticals, Inc. (428.91%), greater than Hepion Pharmaceuticals, Inc. (-328.66%), greater than Freeline Therapeutics Holdings plc (-110.68%), less than AVROBIO, Inc. (29.68%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%),

Build a custom stock screener for Phathom Pharmaceuticals, Inc. (PHAT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Phathom Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Phathom Pharmaceuticals, Inc. (PHAT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Phathom Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.